Pediatric randomized trial EORTC CLG 58951: Outcome for adolescent population with acute lymphoblastic leukemia

Autor: Yves Bertrand, Pierre-Simon Rohrlich, Laura Olivier-Gougenheim, Hélène Cavé, Barbara De Moerloose, Anne Uyttebroeck, Alina Ferster, Stefan Suciu, Carine Domenech, Chloé Arfeuille, Geneviève Plat, N Sirvent
Přispěvatelé: Hospices Civils de Lyon (HCL), AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), European Organization for Research and Treatment of Cancer (EORTC), EORTC, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), CHU Toulouse [Toulouse], Hôpital Universitaire des Enfants Reine Fabiola [Bruxelles, Belgique] (HUDERF), Universiteit Gent = Ghent University [Belgium] (UGENT), University Hospitals Leuven [Leuven], Centre Hospitalier Universitaire de Nice (CHU Nice)
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Male
Cancer Research
Pediatrics
MESH: Remission Induction
MESH: Combined Modality Therapy
Lymphoblastic Leukemia
genetic abnormalities
law.invention
chemistry.chemical_compound
0302 clinical medicine
Randomized controlled trial
law
Antineoplastic Combined Chemotherapy Protocols
Medicine
Young adult
MESH: Treatment Outcome
education.field_of_study
Remission Induction
Hematopoietic Stem Cell Transplantation
clinical trial
[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology
Hematology
General Medicine
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Prognosis
Combined Modality Therapy
3. Good health
MESH: Antineoplastic Combined Chemotherapy Protocols
MESH: Maintenance Chemotherapy
Treatment Outcome
Oncology
030220 oncology & carcinogenesis
outcome
Female
medicine.medical_specialty
Asparaginase
Population
[SDV.CAN]Life Sciences [q-bio]/Cancer
acute lymphoblastic leukemia
MESH: Prognosis
Maintenance Chemotherapy
03 medical and health sciences
Humans
education
MESH: Hematopoietic Stem Cell Transplantation
MESH: Adolescent
MESH: Precursor Cell Lymphoblastic Leukemia-Lymphoma
MESH: Humans
business.industry
Cancer
medicine.disease
MESH: Male
Adolescent population
Clinical trial
chemistry
adolescent
business
MESH: Female
030215 immunology
Zdroj: Hematological Oncology
Hematological Oncology, Wiley, 2020, 38 (5), pp.763-772. ⟨10.1002/hon.2791⟩
ISSN: 0278-0232
1099-1069
DOI: 10.1002/hon.2791⟩
Popis: International audience; Over the years, the prognosis of adolescents treated for acute lymphoblastic leukemia (ALL) has improved. However, this age group still represents a challenge with an overall survival (OS) of 60% compared to 85% in younger children. Herein, we report the outcome of adolescents treated in the European Organisation for Research and Treatment of Cancer (EORTC) 58951 clinical trial. EORTC 58951 clinical trial included patients with de novo ALL between 1998 and 2008. For this study, we analyzed data of all adolescents between 15 and under 18. Data from 97 adolescents were analyzed, 70 had B-lineage and 27 had T-lineage ALL. The 8-year event-free survival (EFS) and OS for the B-cell precursor ALL cases were 72.3% (59.4%-81.7%) and 80.8% (67.4%-89.1%), respectively. For the T-lineage, the 8-year EFS and OS were 57.4% (36.1%-74.0%) and 59.0% (36.1%-76.2%), respectively. "B-other" ALL, defined as BCP-ALL lacking any known recurrent genetic abnormalities were more frequent in our adolescent population (52.8%) than in younger children (27.1%). Outcome of adolescents in the EORTC 58951 study is supporting the findings that adolescents have better outcome in pediatric compared to adults' trials. Nevertheless, in pediatric studies, adolescents still have a worse prognosis than younger children. Despite the fact that specific unfavorable characteristics may be linked to the adolescent population, a careful study and characterization of adolescents "B-other" genetic abnormalities in ALL is critical to improve the outcome of this population.
Databáze: OpenAIRE
Externí odkaz: